Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Classical hematology 1

Conditions

Urinary Bladder Neoplasms 2Urinary Tract Infections 1Tissue Adhesions 1Stomach Neoplasms 1Polyps 1Non-Muscle Invasive Bladder Neoplasms 1Neutropenia 1Neoplasms 1Myoma 1Multiple Myeloma 1Infections 1Hematologic Neoplasms 1Hearing Loss 1Febrile Neutropenia 1Endometritis 1Ear Neoplasms 1Drug-Related Side Effects and Adverse Reactions 1Cystitis 1

Interventions

pembrolizumab 185Gemcitabine 170Paclitaxel 152Carboplatin 137Bevacizumab 128Surveys and Questionnaires 118Cisplatin 115Docetaxel 114Blood Specimen Collection 110Cyclophosphamide 109Exercise 108Nivolumab 99Fluorouracil 90Capecitabine 86Radiotherapy 81Dexamethasone 81Irinotecan 74Standard of Care 69Pemetrexed 68Oxaliplatin 68Drug Therapy 65Leucovorin 64Cetuximab 60Erlotinib Hydrochloride 56atezolizumab 53Sorafenib 53Ipilimumab 51Doxorubicin 50trametinib 47Interviews as Topic 47

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasms × Ofloxacin × Clear all
NCT07590648 2026-05-15

E-STOP2

Hospital Universitari Vall d'Hebron Research Institute

Phase 4 Not yet recruiting
136 enrolled
Classical hematologyOther hematologic neoplasm

Neoplasms, Neutropenia, Hematologic Neoplasms, Febrile Neutropenia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡